Autonomix Medical, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AMIX Nasdaq 3840 autonomix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Autonomix Medical, Inc.

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors - Sep 16th, 2026 6:30 am
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 - Sep 1st, 2026 6:30 am
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery - Aug 26th, 2026 6:30 am
Top Midday Gainers - Aug 25th, 2026 11:16 am
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules - Aug 24th, 2026 7:06 pm
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission - Aug 12th, 2026 6:15 am
Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion - Aug 4th, 2026 9:24 am
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy - Aug 4th, 2026 6:15 am
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study - Jul 24th, 2026 6:47 am
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform - Jul 23rd, 2026 5:30 am
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform - Jul 15th, 2026 6:00 am
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules - Jul 13th, 2026 7:30 pm
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant - Jul 13th, 2026 5:30 am
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change - Jun 22nd, 2026 6:00 am
Autonomix Announces Reverse Stock Split - Jun 18th, 2026 2:30 pm
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine - Jun 4th, 2026 7:05 am
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation - May 19th, 2026 6:30 am
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation - May 18th, 2026 6:45 am
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation - Apr 29th, 2026 6:45 am
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026 - Apr 22nd, 2026 6:42 am